Clinical diagnosis and staging of cholangiocarcinoma, Nat Rev Gastroenterol Hepatol. sept, vol.8, issue.9, pp.512-534, 2011. ,
Multidisciplinary approaches to intrahepatic cholangiocarcinoma, Cancer, vol.15, issue.22, pp.3929-3971, 2013. ,
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?, J Hepatol. mars, vol.40, issue.3, pp.472-479, 2004. ,
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma, J Hepatol. 1 juin, vol.60, issue.6, pp.1268-89, 2014. ,
Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis, JAMA Surg. juin, vol.149, issue.6, pp.565-74, 2014. ,
Cholangiocarcinomaevolving concepts and therapeutic strategies, Nat Rev Clin Oncol, vol.15, issue.2, pp.95-111, 2018. ,
Intrahepatic cholangiocarcinoma: expert consensus statement, HPB. août, vol.17, issue.8, pp.669-80, 2015. ,
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis, J Clin Oncol Off J Am Soc Clin Oncol. 1 juin, vol.30, issue.16, pp.1934-1974, 2012. ,
Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma, Ann Surg Oncol, vol.22, issue.11, pp.3716-3739, 2015. ,
Resection for intrahepatic cholangiocellular cancer: new advances, Transl Gastroenterol Hepatol, vol.3, p.60, 2018. ,
Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection, Ann Surg Oncol. janv, vol.23, issue.1, pp.235-278, 2016. ,
,
, Intrahepatic cholangiocarcinoma: management options and emerging therapies
, J Am Coll Surg, vol.217, issue.4, pp.736-750, 2013.
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA), Nat Rev Gastroenterol Hepatol, vol.13, issue.5, pp.261-80, 2016. ,
Nonalcoholic fatty liver disease: from steatosis to cirrhosis, Hepatol Baltim Md. févr, vol.43, issue.2, pp.99-112, 2006. ,
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatol Baltim Md, vol.64, issue.1, pp.73-84, 2016. ,
Nonalcoholic fatty liver disease: a systematic review, JAMA. 9 juin, vol.313, issue.22, pp.2263-73, 2015. ,
NAFLD in Asia--as common and important as in the West, Nat Rev Gastroenterol Hepatol. mai, vol.10, issue.5, pp.307-325, 2013. ,
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol, vol.2, issue.11, pp.901-911, 2014. ,
, Nat Rev Gastroenterol Hepatol, vol.10, issue.11, pp.656-65, 2013.
,
, Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis, Hepatol Int. juill, vol.10, issue.4, pp.632-641, 2016.
,
, Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database, Hepatol Baltim Md. août, vol.54, issue.2, pp.463-71, 2011.
,
, Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study, Hepatol Baltim Md. déc, vol.56, issue.6, pp.2221-2251, 2012.
,
Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis, BMC Gastroenterol. 8 déc, vol.17, issue.1, p.149, 2017. ,
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?, World J Hepatol. 27 mai, vol.6, issue.5, pp.306-320, 2014. ,
,
, Gastrointest Surg Off J Soc Surg Aliment Tract. août, vol.15, issue.8, pp.1450-1458, 2011.
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the, Hepatol Baltim Md, vol.67, issue.1, pp.328-57, 2018. ,
, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, European Association for the Study of the Liver (EASL), vol.64, pp.1388-402, 2016.
,
, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatol Baltim Md. juill, vol.54, issue.1, pp.344-53, 2011.
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease ,
, Hepatol Baltim Md. août, vol.60, issue.2, pp.565-75, 2014.
Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatol Baltim Md. juin, vol.41, issue.6, pp.1313-1334, 2005. ,
Liver anatomy: portal (and suprahepatic) or biliary segmentation ,
, Dig Surg, vol.16, issue.6, pp.459-67, 1999.
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey ,
, Ann Surg. août, vol.240, issue.2, pp.205-218, 2004.
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatol Baltim Md, vol.67, issue.1, pp.123-156, 2018. ,
,
, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatol Baltim Md. mars, vol.49, issue.3, pp.851-860, 2009.
,
, Nonalcoholic fatty liver disease -A multisystem disease?, World J Gastroenterol, vol.22, issue.43, pp.9488-505, 2016.
Nonalcoholic fatty liver disease as a multi-systemic disease, World J Gastroenterol. 28 avr, vol.22, issue.16, pp.4079-90, 2016. ,
Hepatic steatosis is associated with surgical-site infection after hepatic and colorectal surgery, Surgery. juill, vol.156, issue.1, pp.109-125, 2014. ,
Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy, J Gastrointest Surg Off J Soc Surg Aliment Tract, vol.16, issue.11, pp.2064-73, 2012. ,
Metabolic syndrome and hepatic resection: improving outcome, HPB. déc, vol.13, issue.12, pp.846-59, 2011. ,
, Liver Resection for
, Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma, J Am Coll Surg. 6 août, 2019.
,
, Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, Lancet Lond Engl. 22 mars, vol.371, issue.9617, pp.1007-1023, 2008.
Strategies for safer liver surgery and partial liver transplantation, N Engl J Med. 12 avr, vol.356, issue.15, pp.1545-59, 2007. ,
Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents, Atherosclerosis. avr, vol.203, issue.2, pp.563-571, 2009. ,
A cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers, PloS One, vol.7, issue.5, p.37241, 2012. ,
Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease, Clin Mol Hepatol. déc, vol.18, issue.4, pp.383-90, 2012. ,
Shortand Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome, World J Surg, vol.43, issue.8, pp.2048-60, 2019. ,
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, vol.65, issue.8, pp.1359-68, 2016. ,
,
, Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow
, Liver Cancer. avr, vol.5, issue.2, pp.107-127, 2016.
The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: A clinicopathologic and immunohistochemical study, Surgery, vol.160, issue.3, pp.683-90, 2016. ,
,
,
, Decreased intratumoral arteries reflect portal tract destruction and aggressive characteristics in intrahepatic cholangiocarcinoma, Histopathology. mars, vol.54, issue.4, pp.452-61, 2009.
Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers, Liver Int Off J Int Assoc Study Liver. août, vol.32, issue.7, 2012. ,
, Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study, Lancet Oncol. mai, vol.20, issue.5, pp.663-73, 2019.
,
, Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study, J Clin Oncol Off J Am Soc Clin Oncol. 10 mars, vol.37, issue.8, pp.658-67, 2019.
,
, Multicentre study of the impact of morbidity on long-term survival following hepatectomy for intrahepatic cholangiocarcinoma, Br J Surg, vol.103, issue.13, pp.1887-94, 2016.
,
, Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program, J Clin Oncol Off J Am Soc Clin Oncol. 20 sept, vol.32, issue.27, pp.2975-84, 2014.
,
, A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience, JAMA Surg. mai, vol.149, issue.5, pp.432-440, 2014.
Recurrence after operative management of intrahepatic cholangiocarcinoma, Surgery. juin, vol.153, issue.6, pp.811-819, 2013. ,
Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy, J Clin Oncol Off J Am Soc Clin Oncol. 20 mars, vol.31, issue.9, pp.1188-95, 2013. ,
Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients, Arch Surg Chic Ill, vol.147, issue.12, pp.1107-1120, 1960. ,
A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score, Ann Oncol Off J Eur Soc Med Oncol. juill, vol.22, issue.7, pp.1644-52, 2011. ,
Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group, Ann Surg, vol.254, issue.5, pp.824-833, 2011. ,
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment, J Clin Oncol Off J Am Soc Clin Oncol. 10 août, vol.29, issue.23, pp.3140-3145, 2011. ,
The impact of perioperative red blood cell transfusions in patients undergoing liver resection: a systematic review protocol, Syst Rev. 29 févr, vol.5, p.38, 2016. ,
,
, Has Nodal Evaluation Been Increasingly Adopted by Surgeons over Time?A National Database Analysis
, J Gastrointest Surg Off J Soc Surg Aliment Tract, vol.22, issue.4, pp.668-75, 2018.
Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System, J Gastrointest Surg Off J Soc Surg Aliment Tract, vol.22, issue.1, pp.52-61, 2018. ,
Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma, J Surg Oncol. mai, vol.113, issue.6, pp.685-91, 2016. ,
Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma? A review of 17 years of experience in a tertiary institution, Surgery. avr, vol.157, issue.4, pp.666-75, 2015. ,
Intrahepatic cholangiocarcinoma patients without indications of lymph node metastasis not benefit from lymph node dissection, Oncotarget. 26 déc, vol.8, issue.69, pp.113817-113844, 2017. ,
Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients, Eur J Gastroenterol Hepatol. janv, vol.25, issue.1, pp.94-102, 2013. ,